Compass Pathways plc and Greenbrook TMS Inc. jointly announced that they have entered into a three-year research collaboration agreement to explore delivery models for investigational COMP360 psilocybin treatment upon regulatory approval by the U.S. Food and Drug Administration (FDA). The collaboration will research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval. The initial phase of the collaboration will comprise research into the delivery of COMP360 at treatment centers across the United States, such as through Greenbrook TMS's current network of treatment centers, working with their patient populations, which include people suffering with treatment-resistant depression (TRD) and other mental health conditions.

In-depth research will include exploring how to improve the patient care experience and gaining a better understanding of therapist needs and investigating the potential use and integration of digital tools within Greenbrook TMS's existing care pathways. COMP360 has been designated a Breakthrough Therapy by the FDA for TRD. Compass has commenced a phase 3 clinical program of COMP360 in TRD and intends to apply for FDA approval upon completion of clinical trials.